A. Samatar

发表

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

J. Larkin, J. Sosman, A. Ribas, 2015, Cancer cell.

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Shuxia Zhao, Leigh Zawel, Stephen Fawell, 2013, Cancer discovery.

Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.

J. English, P. Kirschmeier, W. Windsor, 2014, Journal of medicinal chemistry.

Network-level effects of kinase inhibitors modulate TNF-α–induced apoptosis in the intestinal epithelium

D. Lauffenburger, K. Lau, Levi B. Wood, 2015, Science Signaling.

Discovery of hydroxyaniline amides as selective Extracellular Regulated Kinase (Erk) inhibitors.

W. Windsor, A. Samatar, D. Carr, 2015, Bioorganic & medicinal chemistry letters.

Biochemical Characterization of a Human Band 4.1-related Protein-tyrosine Phosphatase, PTPH1 (*)

Qing Yang, N. Tonks, Q. Yang, 1995, The Journal of Biological Chemistry.

Musings on Global Citizenship

A. Samatar, 2007 .

An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer

A. Welm, S. Oesterreich, Zheqi Li, 2021, Breast Cancer Research.

Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling.

C. Kumar, Z. Yin, Y. Liu, 2001, Biochimica et biophysica acta.

Development of a Fluorescence Polarization Bead-Based Coupled Assay to Target Different Activity/Conformation States of a Protein Kinase

P. Kirschmeier, C. Kumar, S. Koseoglu, 2004, Journal of biomolecular screening.

Targeting RAS–ERK signalling in cancer: promises and challenges

P. Poulikakos, A. Samatar, Poulikos I. Poulikakos, 2014, Nature Reviews Drug Discovery.

Discovery of ZN-c3, a Highly Potent and Selective Wee1 Inhibitor Undergoing Evaluation in Clinical Trials for the Treatment of Cancer.

A. Samatar, Sunny Abraham, S. Paliwal, 2021, Journal of medicinal chemistry.

Transforming Growth Factor-β2 Is a Transcriptional Target for Akt/Protein Kinase B via Forkhead Transcription Factor*

Luquan Wang, A. Mirza, Suxing Liu, 2002, The Journal of Biological Chemistry.

Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors

Kathleen M. Smith, T. Mcclanahan, P. Kirschmeier, 2006, Cancer biology & therapy.

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

E. Petricoin, A. Maitra, K. Wennerberg, 2016, Cancer cell.

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma

M. Herlyn, K. Nathanson, M. Xiao, 2016, Oncotarget.

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK

A. Heck, J. Beijnen, D. Peeper, 2015, Pigment cell & melanoma research.

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

T. Graeber, A. Ribas, R. Lo, 2014, Molecular Cancer.

Dissecting Therapeutic Resistance to ERK Inhibition

L. Zawel, S. Fawell, L. Jayaraman, 2016, Molecular Cancer Therapeutics.

Identification of TGF-βII as a transcriptional target of Akt

Luquan Wang, M. Ramachandra, Suxing Liu, 2001, Nature Genetics.

Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.

C. Der, A. Samatar, Leanna R. Gentry, 2013, The Enzymes.

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

T. Graeber, A. Ribas, R. Lo, 2015, Molecular Cancer.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

W. R. Bishop, R. Sullivan, K. Flaherty, 2018, JCI insight.

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

K. Cox, P. Kirschmeier, R. Doll, 2018, ACS medicinal chemistry letters.

Extracellular Signal-Regulated Kinase (ERK1 and ERK2) Inhibitors

A. Samatar, 2017 .

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.

P. Kirschmeier, R. Doll, W. Windsor, 2018, Bioorganic & medicinal chemistry letters.

Abstract 4373: Discovery of ZN-c5, a novel potent and oral selective estrogen receptor degrader

F. Doñate, A. Samatar, Robert Winkler, 2020 .

562TiP A phase Ib dose-escalation study of ZN-c3, a WEE1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian, peritoneal, or fallopian tube cancer

D. Voliotis, F. Doñate, A. Samatar, 2021, Annals of Oncology.

526P Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3

A. Tolcher, F. Meric-Bernstam, D. Voliotis, 2021, Annals of Oncology.